LEGN · Legend Biotech

The thesis

Legend Biotech's shares are more likely to lag the S&P 500 over the next three months. The third-quarter report on 10 November 2026 showed a second straight profit, but CARVYKTI growth slowed and the market sold the shares hard. Two events settle the call: the FDA decision on Gilead and Arcellx's competing anito-cel, due 23 December 2026, and fourth-quarter CARVYKTI sales, expected in January 2027.

The $21.56 kill line was crossed on 10 November 2026, when the shares closed at $20.41, down from $24.29 the session before. That close showed the market did not read the profit as enough to support the price. The shares fell again to $19.54 on 11 November 2026, the day Oppenheimer, Morgan Stanley, Barclays and RBC Capital all cut their targets. The rating is Low because the crossing came with a slowdown in growth and a round of lower targets, while the main competitive test is still ahead.

The profit itself held. Legend's 6-K for the quarter reported International Financial Reporting Standards (IFRS) net income of $51.7 million, against a $39.6 million loss a year earlier, and adjusted net income of $55.6 million, or $0.14 per share. The shares closed at $19.54 on 11 November 2026, 47.9% below the 52-week high of $37.50 set on 3 June 2026. At that price the market is weighing slower growth and the anito-cel threat more heavily than the profit.

Bullish and bearish views on Legend Biotech Corporation

The bull case on Legend Biotech Corporation (LEGN), in brief: the profit repeated. The bear case: growth slowed. CARVYKTI net trade sales of about $710 million rose 36% year over year in the third quarter, against 50% growth in the second quarter. In the US, sales grew 19%, against 86% outside the US (Q3 2026 6-K and 10 November 2026 call). Revenue fell from the second…

Bull case

• The profit repeated. Third-quarter operating income was $46.8 million, against a $43.3 million operating loss a year earlier (Q3 2026 6-K, 10 November 2026). That follows $63.1 million of adjusted net income in the second quarter, Legend's first adjusted profit.
• Revenue is still well above last year. Total revenue was $359.5 million in the third quarter of 2026, against $272.4 million a year earlier. Collaboration revenue was $353.2 million (Q3 2026 6-K).
• Use is moving into earlier lines. Second- and third-line patients made up 50% of US apheresis volume in the third quarter, up from 41% in the first quarter of 2026 and 29% in the first quarter of 2025 (10 November 2026 earnings call). Management said only 15% to 20% of those patients have already had a BCMA therapy.
• Leadership is settled. Ingrid Zhang became chief executive effective 15 September 2026 (Q3 2026 6-K). On the 10 November 2026 call she said she remains confident CARVYKTI can exceed $5 billion in peak sales.
• Most brokers still sit well above the price. Even after their 11 November 2026 cuts, Barclays' target is $61, RBC Capital's is $50 and Morgan Stanley's is $43. All three kept positive ratings.
• Durability data are strong. In CARTITUDE-2 Cohort A, 10 of 20 patients were alive and progression-free at five years without further treatment (data presented September 2026, cited in the Q3 2026 6-K).

Bear case

• Growth slowed. CARVYKTI net trade sales of about $710 million rose 36% year over year in the third quarter, against 50% growth in the second quarter. In the US, sales grew 19%, against 86% outside the US (Q3 2026 6-K and 10 November 2026 call).
• Revenue fell from the second quarter. Third-quarter revenue of $359.5 million compares with $387.5 million in the second quarter. It also came in under the $361.6 million estimate quoted in the 10 November 2026 results headline.
• Cash fell despite the profit. Cash, cash equivalents and time deposits were about $853 million at 30 September 2026, against about $965 million at 30 June 2026 (Q2 and Q3 2026 releases).
• Targets came down across the board. On 11 November 2026, Oppenheimer cut its target from $40 to $25 at Perform, Morgan Stanley from $49 to $43, Barclays from $68 to $61 and RBC Capital from $56 to $50.
• A competitor's FDA decision is due on 23 December 2026. Anito-cel from Gilead and Arcellx is a BCMA CAR-T therapy aimed at the same later-line myeloma patients. A cleaner safety label could cut into CARVYKTI's US share.
• Frontline upside is distant. Management said on 10 November 2026 that the frontline trial readouts will come no earlier than 2027 and depend on patient events. That leaves no clinical lift for the US business in the near term.

Price setup

The shares closed at $19.54 on 11 November 2026. That is under both the 50-day moving average of $19.72 and the 200-day moving average of $22.19, measured on adjusted daily closes as of that date. The two-session drop from $24.29 on 9 November 2026 wiped out the climb from $22.54 on 5 November 2026 into the report.

The 3-month price change to 11 November 2026 is −3.6%, from a $20.27 close on 13 August 2026. The 52-week closing low is $16.65, set on 4 February 2026, and the 52-week high is $37.50, set intraday on 3 June 2026. The June 2026 offering priced at $29.35 per American depositary share (ADS), far above where the shares now trade.

A return above the 200-day moving average would show the market reversing its reading of the report. A move toward the February closing low would mean it is pricing CARVYKTI's slowdown as lasting.

Catalysts ahead

• December 2026 (est.): American Society of Hematology (ASH) annual meeting, where Legend has multiple accepted abstracts. New CARVYKTI and pipeline data shape the comparison of durability and safety against competing BCMA CAR-T therapies ahead of the anito-cel decision.
• 23 December 2026: FDA action date for anito-cel (Gilead/Arcellx) in relapsed/refractory multiple myeloma. An approval with a cleaner safety label would threaten CARVYKTI's later-line US share, the market that drives Legend's growth.
• January 2027 (est.): Preliminary fourth-quarter 2026 CARVYKTI net trade sales from Johnson & Johnson and Legend. These figures show whether US growth picks up again from 19% year over year or keeps slowing.

What would change the view

A daily close above $22.19, the 200-day moving average as of 11 November 2026, which would show the shares recovering from the post-report drop. Fourth-quarter 2026 adjusted net income above the third quarter's $55.6 million would also show them leading.

The line before it, a daily close below $21.56 set on 10 November 2026, was crossed on 10 November 2026: the shares closed at $20.41.

What it trades with

Legend splits CARVYKTI economics roughly 50/50 with Johnson & Johnson. Its Janssen unit reports the global net trade sales, so Johnson & Johnson's quarterly figures move the shares. The anito-cel decision from Gilead and Arcellx is the closest competitive read-through. Legend does substantial research and development in China, so US-China biotech policy headlines are a second source of movement. Beyond those, the shares trade with the oncology and cell-therapy group.